These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33938589)

  • 21. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Application of immune combination therapy in MSS/pMMR-type colorectal cancer: current status and future perspectives].
    Zhang XL; Fan WX; Du YY; Zhang Y; Su F; Hu WQ; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2024 Aug; 46(8):725-736. PubMed ID: 39143795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
    Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
    BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges.
    Shahnazari M; Samadi P; Pourjafar M; Jalali A
    Future Oncol; 2021 Aug; 17(24):3253-3270. PubMed ID: 34156258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subtyping of microsatellite instability-high colorectal cancer.
    Hu W; Yang Y; Qi L; Chen J; Ge W; Zheng S
    Cell Commun Signal; 2019 Jul; 17(1):79. PubMed ID: 31331345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Thomsen-Friedenreich Antigen in Colorectal Cancer and Association with Microsatellite Instability.
    Leão B; Wen X; Duarte HO; Gullo I; Gonçalves G; Pontes P; Castelli C; Diniz F; Mereiter S; Gomes J; Carneiro F; Reis CA
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of single-source dual-energy CT imaging for discriminating microsatellite instability from microsatellite stability human colorectal cancer.
    Wu J; Lv Y; Wang N; Zhao Y; Zhang P; Liu Y; Chen A; Li J; Li X; Guo Y; Wu T; Liu A
    Eur Radiol; 2019 Jul; 29(7):3782-3790. PubMed ID: 30903331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
    Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of microsatellite stability status in colorectal cancer.
    Gupta R; Sinha S; Paul RN
    Curr Probl Cancer; 2018 Nov; 42(6):548-559. PubMed ID: 30119911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 37. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
    Wang D; Zhang H; Xiang T; Wang G
    Front Immunol; 2021; 12():762341. PubMed ID: 34721435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
    Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.